Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novamind Inc. NVMDF

Healthcare Biotechnology
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence... see more

Recent & Breaking News (OTCQB:NVMDF)

Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety

Accesswire March 16, 2022

Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety

Accesswire March 16, 2022

Novamind Grants Restricted Share Units

Accesswire March 11, 2022

Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder

Accesswire March 9, 2022

Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights

Accesswire March 1, 2022

Novamind Publishes Psychedelic Therapy Patient Case Studies

Accesswire February 22, 2022

Novamind advances clinical pilot for frontline KAP

Stockhouse Editorial February 17, 2022

Novamind Advances Clinical Pilot for Frontline KAP

Accesswire February 16, 2022

Novamind Participates in Alto Neuroscience Phase II Clinical Trial for MDD and PTSD

Accesswire February 9, 2022

Novamind Appoints Prakash Gowd as COO

Stockhouse Editorial February 8, 2022

Novamind Appoints Prakash Gowd as Chief Operating Officer

Accesswire February 8, 2022

Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients

Accesswire February 3, 2022

The StockTalk Cannabis Report: Jan 28, 2022

Dave Jackson January 28, 2022

Novamind announces closing of CDN$5M private placement with institutional investor

Stockhouse Editorial January 27, 2022

Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor

Accesswire January 26, 2022

Novamind Announces CAD$5 Million Private Placement with Institutional Investor

Accesswire January 24, 2022

Novamind to Participate in Citi's Psychedelic Drug Video Call Series

Accesswire January 20, 2022

Novamind Closes Arizona Acquisition

Accesswire January 18, 2022

Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder

Accesswire January 13, 2022

Novamind Unveils New Design Concept for Clinics

Accesswire January 5, 2022